PMID- 23419641
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20221207
IS  - 1876-4738 (Electronic)
IS  - 0914-5087 (Linking)
VI  - 61
IP  - 4
DP  - 2013 Apr
TI  - Efficacy and safety of a 60-week treatment with candesartan in Japanese patients 
      with mild to moderate chronic heart failure.
PG  - 267-74
LID - S0914-5087(13)00007-5 [pii]
LID - 10.1016/j.jjcc.2012.12.004 [doi]
AB  - BACKGROUND: Chronic heart failure (CHF) is an increasingly common cardiovascular 
      disease despite recent advances in its diagnosis and management. METHODS AND 
      RESULTS: A multicenter, open-label study was designed to assess the efficacy and 
      safety of 60-week treatment with candesartan in Japanese patients with mild to 
      moderate CHF. Primary efficacy endpoints were changes from baseline in plasma 
      brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), 
      end-diastolic dimension, and New York Heart Association (NYHA) functional class. 
      Two hundred and eighty-nine eligible patients were divided into 2 groups based on 
      the daily dose at the end of treatment: high-dose (HD, 8mg, N=170) and low-dose 
      (LD, 2 or 4mg, N=119). Neither plasma BNP levels nor LVEF changed from the 
      baseline to the end of treatment in the LD group, whereas BNP significantly 
      improved from 61.6 to 50.1pg/mL (p=0.0005) and LVEF from 57.2 to 60.1% (p=0.0005) 
      in the HD group. The changes in NYHA functional class were comparable between 
      groups: 21.2% improved and 76.3% unchanged in the LD group and 20.6% improved and 
      79.4% unchanged in the HD group. No safety concerns were observed in either 
      group. CONCLUSIONS: HD candesartan was more effective in improving plasma BNP 
      levels and cardiac function than LD in Japanese CHF patients. Both LD and HD 
      candesartan were well tolerated in CHF patients.
CI  - Copyright (c) 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Matsuzaki, Masunori
AU  - Matsuzaki M
AD  - Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi 
      University Graduate School of Medicine, Ube, Japan.
FAU - Yamamoto, Kazuhiro
AU  - Yamamoto K
FAU - Yano, Masafumi
AU  - Yano M
FAU - Nakamura, Koki
AU  - Nakamura K
FAU - Miyata, Yuko
AU  - Miyata Y
FAU - Sugiura, Kenkichi
AU  - Sugiura K
FAU - Nakata, Emi
AU  - Nakata E
FAU - Tsutsui, Hiroyuki
AU  - Tsutsui H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20130216
PL  - Netherlands
TA  - J Cardiol
JT  - Journal of cardiology
JID - 8804703
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biomarkers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - S8Q36MD2XX (candesartan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Angiotensin II Type 1 Receptor Blockers/*administration & dosage
MH  - Asian People
MH  - Benzimidazoles/*administration & dosage
MH  - Biomarkers/blood
MH  - Biphenyl Compounds
MH  - Chronic Disease
MH  - Female
MH  - Heart Failure/blood/*drug therapy/physiopathology
MH  - Heart Function Tests
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Tetrazoles/*administration & dosage
MH  - Time Factors
EDAT- 2013/02/20 06:00
MHDA- 2013/09/27 06:00
CRDT- 2013/02/20 06:00
PHST- 2012/10/02 00:00 [received]
PHST- 2012/11/28 00:00 [revised]
PHST- 2012/12/06 00:00 [accepted]
PHST- 2013/02/20 06:00 [entrez]
PHST- 2013/02/20 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - S0914-5087(13)00007-5 [pii]
AID - 10.1016/j.jjcc.2012.12.004 [doi]
PST - ppublish
SO  - J Cardiol. 2013 Apr;61(4):267-74. doi: 10.1016/j.jjcc.2012.12.004. Epub 2013 Feb 
      16.